Tags

Type your tag names separated by a space and hit enter

[Efficacy of ingavirin in adults with influenza].
Ter Arkh. 2009; 81(3):51-4.TA

Abstract

AIM

To compare therapeutic efficacy and safety of ingavirin and arbidol in patients with influenza.

MATERIAL AND METHODS

The trial included 105 patients with a verified diagnosis of influenza, definite clinical symptoms, body temperature at least 38 degrees C and duration of the disease 36 hours maximum. Ingavirin efficacy was analysed basing on the evidence for 100 patients with uncomplicated influenza. The patients were randomized into three groups: taking ingavirin in a single daily dose 90 mg (n = 33), placebo (n = 36) or arbidol (200 mg 4 times a day). The duration of the treatment was 5 days.

RESULTS

Intake of ingavirin in initial 24-36 hours of the disease significantly reduced fever compared to placebo and arbidol (34.5, 72.0 and 48.4 hours, respectively). Ingavirin was less toxic and had no side effects.

CONCLUSION

Ingavirin is safe and effective in the treatment of influenza. By some criteria it is more effective than arbidol.

Authors

Kolobukhina LV
No affiliation info available
Merkulova LN
No affiliation info available
Shchelkanov MIu
No affiliation info available
Burtseva EI
No affiliation info available
Isaeva EI
No affiliation info available
Malyshev NA
No affiliation info available
L'vov DK
No affiliation info available

MeSH

AdolescentAdultAmidesAntiviral AgentsCaproatesDicarboxylic AcidsFemaleHumansImidazolesIndolesInfluenza, HumanMaleMiddle AgedYoung Adult

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

rus

PubMed ID

19459424

Citation

Kolobukhina, L V., et al. "[Efficacy of Ingavirin in Adults With Influenza]." Terapevticheskii Arkhiv, vol. 81, no. 3, 2009, pp. 51-4.
Kolobukhina LV, Merkulova LN, Shchelkanov MIu, et al. [Efficacy of ingavirin in adults with influenza]. Ter Arkh. 2009;81(3):51-4.
Kolobukhina, L. V., Merkulova, L. N., Shchelkanov, M. I. u., Burtseva, E. I., Isaeva, E. I., Malyshev, N. A., & L'vov, D. K. (2009). [Efficacy of ingavirin in adults with influenza]. Terapevticheskii Arkhiv, 81(3), 51-4.
Kolobukhina LV, et al. [Efficacy of Ingavirin in Adults With Influenza]. Ter Arkh. 2009;81(3):51-4. PubMed PMID: 19459424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Efficacy of ingavirin in adults with influenza]. AU - Kolobukhina,L V, AU - Merkulova,L N, AU - Shchelkanov,M Iu, AU - Burtseva,E I, AU - Isaeva,E I, AU - Malyshev,N A, AU - L'vov,D K, PY - 2009/5/23/entrez PY - 2009/5/23/pubmed PY - 2009/6/23/medline SP - 51 EP - 4 JF - Terapevticheskii arkhiv JO - Ter Arkh VL - 81 IS - 3 N2 - AIM: To compare therapeutic efficacy and safety of ingavirin and arbidol in patients with influenza. MATERIAL AND METHODS: The trial included 105 patients with a verified diagnosis of influenza, definite clinical symptoms, body temperature at least 38 degrees C and duration of the disease 36 hours maximum. Ingavirin efficacy was analysed basing on the evidence for 100 patients with uncomplicated influenza. The patients were randomized into three groups: taking ingavirin in a single daily dose 90 mg (n = 33), placebo (n = 36) or arbidol (200 mg 4 times a day). The duration of the treatment was 5 days. RESULTS: Intake of ingavirin in initial 24-36 hours of the disease significantly reduced fever compared to placebo and arbidol (34.5, 72.0 and 48.4 hours, respectively). Ingavirin was less toxic and had no side effects. CONCLUSION: Ingavirin is safe and effective in the treatment of influenza. By some criteria it is more effective than arbidol. SN - 0040-3660 UR - https://www.unboundmedicine.com/medline/citation/19459424/[Efficacy_of_ingavirin_in_adults_with_influenza]_ L2 - https://medlineplus.gov/flu.html DB - PRIME DP - Unbound Medicine ER -